Classen Immunotherapies Inc. Release: Further Evidence Epidemics of both Type 1 Diabetes (insulin dependent) and Type 2 Diabetes/Obesity are Linked to Immunization

BALTIMORE, Sept. 1, 2011 /PRNewswire/ -- The following was issued today by Classen Immunotherapies, Inc.:

Data published in the August edition of the Journal of Pediatric Endocrinology and Metabolism provides further evidence that epidemics of type 2 diabetes/obesity/metabolic syndrome are linked to the epidemic of type 1 diabetes which has been shown to be caused by vaccines.

The new data derived from large populations of children in Italy confirms previously published work that obesity is actually associated with a protective effect on type 1 diabetes. In Italy regions where obesity has a high prevalence there is low prevalence of type 1 diabetes and in areas where there is a high incidence of type 1 diabetes there is a low prevalence of obesity. In the areas where type 1 diabetes has a high prevalence there is a high frequency of genetic traits that predispose to low cortisol production.

The data along with previously published papers shows an alarming trend. Vaccines are causing an epidemic of type 1 diabetes and related autoimmune diseases in children. The children which are most susceptible to this are low cortisol producers. In other children vaccine induced inflammation leads to production of excessive cortisol and other immune suppressive mediators causing an epidemic of obesity and type 2 diabetes in these children.

The data sheds light on another alarming trend. Parents, especially of minority races that produce high cortisol responses, are being blamed for their children's obesity. Both the parents as well as the obese patients face harassment and prejudice leading to erosion of self esteem and a sense of guilt. This discrimination is totally misplaced as diet and exercise are not an effective treatment of an vaccine related adverse event.

To view the published papers and to find out the latest information on the effects of vaccines on autoimmune diseases including insulin dependent diabetes visit the Vaccine Safety Web site

Classen Immunotherapies, Inc. Tel: 410-377-8526

SOURCE Classen Immunotherapies, Inc.

Back to news